Atara Biotherapeutics (ATRA) Price to Book (2014 - 2026)

Atara Biotherapeutics (ATRA) has reported Price to Book for 13 consecutive years, with 4.66 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book fell 73.6% year-over-year to 4.66; the trailing twelve-month figure through Jun 2026 stood at 4.66 (down 73.6% YoY), and the FY2025 full-year result was 5.89, down 3056.77% from the prior year.
• Price to Book retreated to 4.66 in Q2 2026 per ATRA's latest filing, from 1.79 in the prior quarter.
• Across five years, Price to Book topped out at 21.84 in Q2 2023 and bottomed at 5.89 in Q4 2025.
• Historically, Price to Book has averaged 0.65 across 5 years, with a median of 0.57 in 2024.
• The sharpest annual moves came in 2023 and 2026: Price to Book soared 664.95% in 2023, then plunged 1495.91% in 2026.
• Over 5 years, Price to Book stood at 2.48 in 2022, then sank by 77.86% to 0.55 in 2023, then slumped by 286.24% to 1.02 in 2024, then tumbled by 475.29% to 5.89 in 2025, then advanced by 20.85% to 4.66 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 4.66, 1.79, and 5.89 for Q2 2026, Q1 2026, and Q4 2025 respectively.